Overview of KAHF Technology:
A Solution for Early Stage Cancer and Metastatic Patients
Lead Program: Pancreatic Ductal Adenocarcinoma (PDAC)
KAHF Biotech is pioneering a breakthrough approach to treating pancreatic and other solid tumors by targeting the KAHF receptor, a novel driver of cancer progression and metastasis. In preclinical studies (GEMM and Orthotopic Models), KAHF receptor inhibition suppressed metastasis in early-stage PDAC, eliminated micro-metastatic tumor cells, and sensitized resistant tumors to standard therapies.
We are advancing a first-in-class therapeutic antibody (Anti-KAHF mAb) designed to block this receptor and disrupt the molecular pathways driving tumor invasion, progression, metastasis, and immune evasion. Our goal is to deliver a transformative new treatment for patients with pancreatic and other aggressive cancers.
Expanding Horizons: KAHF Biotech Pursuing Next-Generation Therapeutic Platforms
Leading the next frontier in oncology, KAHF Biotech develops Antibody–Oligonucleotide and Degrader Antibody Conjugates. Through smart, precision-driven design, we target undruggable cancer proteins, transforming them into actionable therapeutic opportunities.